TNF blockers may increase the risk of malignancy in children, study finds
Monday, August 2, 2010 - 07:35
in Health & Medicine
The Food and Drug Administration received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab.